September 23, 2008 -Novel Pan Bcl-2 Inhibitor is a Potential Treatment for Broad Range of Cancers - Gemin X, a clinical stage biopharmaceutical company developing novel, targeted cancer therapeutics, announced that the United States Patent & Trademark Office issued to Gemin X a patent protecting the composition of matter of obatoclax through 2025 - U.S. Patent No. 7,425,553. One of Gemin X's lead pipeline programs, obatoclax is an oncology treatment based on programmed cell death, or apoptosis, and has the potential to be a first-in-class pan Bcl-2 inhibitor. Obatoclax is currently in Phase 2 clinical trials for the treatment of elderly acute myeloid leukemia and the treatment of small cell lung cancer... Gemin X's Press Release -
Oct 3, 2008
Gemin X : Key U.S. Patent Issued for Obatoclax
September 23, 2008 -Novel Pan Bcl-2 Inhibitor is a Potential Treatment for Broad Range of Cancers - Gemin X, a clinical stage biopharmaceutical company developing novel, targeted cancer therapeutics, announced that the United States Patent & Trademark Office issued to Gemin X a patent protecting the composition of matter of obatoclax through 2025 - U.S. Patent No. 7,425,553. One of Gemin X's lead pipeline programs, obatoclax is an oncology treatment based on programmed cell death, or apoptosis, and has the potential to be a first-in-class pan Bcl-2 inhibitor. Obatoclax is currently in Phase 2 clinical trials for the treatment of elderly acute myeloid leukemia and the treatment of small cell lung cancer... Gemin X's Press Release -
